Logo
x

Search

Subscribe Now

ViiV Healthcare

ViiV Healthcare, GSK & Pfizer’s Global Specialist HIV Company, Reports P-III (LATITUDE) Study Results of Cabenuva (cabotegravir + rilpivirine) for HIV

ViiV Healthcare, GSK & Pfizer’s Global Specialist HIV Company, Reports P-III (LATITUDE) Study Results of Cabenuva (cabotegravir +...

  • February 21, 2024
ViiV Healthcare's Vocabria in Combination with Rekambys Receives the NMPA’s Approval as an HIV-1 Injectable Treatment

ViiV Healthcare's Vocabria in Combination with Rekambys Receives the NMPA’s Approval as an HIV-1 Injectable Treatment

  • October 26, 2023
ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention

ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention

  • September 19, 2023
ViiV Healthcare Receives EMA’s CHMP Positive Opinion of Cabotegravir for HIV Prevention

ViiV Healthcare Receives EMA’s CHMP Positive Opinion of Cabotegravir for HIV Prevention

  • July 24, 2023
Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

  • May 19, 2023
ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1

ViiV Healthcare Receives EC's Marketing Authorisation of Triumeq PD for the Treatment of Human Immunodeficiency Virus Type 1

  • February 22, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.